Table 7.
Antimicrobials used in PHO and HCT patients with SI.
| Antibiotic | PHO (n = 1652) | HCT (n = 325) |
|---|---|---|
| Amikacin | 341 (20.6%) | 60 (18.5%) |
| Amoxicillin/clavulanic acid | 111 (6.7%) | 10 (3.1%) |
| Cefepime | 167 (10.1%) | 30 (9.2%) |
| Cefotaxime | 30 (1.8%) | 0 (0.0%) |
| Ceftazidime | 132 (8.0%) | 7 (2.2%) |
| Ceftriaxone | 75 (4.5%) | 3 (0.9%) |
| Cefuroxime | 44 (2.7%) | 5 (1.5%) |
| Ciprofloxacin | 60 (3.6%) | 12 (3.7%) |
| Clindamycin | 45 (2.7%) | 1 (0.3%) |
| Cloxacillin | 95 (5.8%) | 8 (2.5%) |
| Gentamicin | 10 (0.6%) | 1 (0.3%) |
| Imipenem | 21 (1.3%) | 4 (1.2%) |
| Levofloxacin | 6 (0.4%) | 2 (0.6%) |
| Linezolid | 103 (6.2%) | 45 (13.8%) |
| Meropenem | 314 (19.0%) | 71 (21.8%) |
| Metronidazole | 83 (5.0%) | 1 (0.3%) |
| Piperacillin/tazobactam | 321 (19.4%) | 46 (14.2%) |
| Rifampicin | 5 (0.3%) | 2 (0.6%) |
| Teicoplanin | 271 (16.4%) | 91 (28.0%) |
| Tigecycline | 0 (0.0%) | 3 (0.9%) |
| Trimethoprim/sulfamethoxazole | 6 (0.4%) | 0 (0.0%) |
| Vancomycin | 906 (54.8%) | 168 (51.7%) |
n—number of infection episodes with available antimicrobial treatment data. Percentages were calculated using n as the denominator in each group.